Pilot Study of Minocycline in Huntington's Disease

Status Completed

Clinical Trial Summary

This study is being conducted to assess the impact of minocycline on the progression of symptoms of HD. The study will also assess whether it is reasonable to continue with further study of minocycline in HD. We will measure the effect of minocycline on HD by measuring the change in Huntington's disease symptoms.

Clinical Trial Description

The DOMINO study is a randomized, double-blind, multi-center, futility study of minocycline in patients with HD. Subjects will be randomized (3:1) to one of the two study arms: (1) the group that receives active minocycline (100 mg po b.i.d.), and (2) the group that receives placebo. Subjects will be enrolled over an approximate six-month period and remain on blinded study drug for 18 months. The primary analysis will involve a comparison of the change over time in TFC between the minocycline group and a fixed value determined from historical control data. A placebo group will also be included to facilitate blinding and to permit a descriptive assessment of the validity of the assumed change over time in historical controls. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Huntington Disease

Clinical Trial Details

NCT number	NCT00277355
Study type	Interventional
Source	Huntington Study Group
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	April 2006
Completion date	November 2008

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03052712` - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies	N/A
Not yet recruiting	`NCT04429230` - Non-invasive Brain Stimulation in Huntington's Disease	N/A
Recruiting	`NCT05032196` - Study of WVE-003 in Patients With Huntington's Disease	Phase 1/Phase 2
Recruiting	`NCT03599076` - Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
Terminated	`NCT04617860` - Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease	Phase 1/Phase 2
Completed	`NCT05748288` - Development of the Virtual Unified Huntington's Disease Rating Scale
Not yet recruiting	`NCT05360082` - Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Not yet recruiting	`NCT04370470` - Development of Assessments for Later Stage HD
Recruiting	`NCT01834053` - Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.	Phase 1/Phase 2
Completed	`NCT01458470` - A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease	Phase 2
Completed	`NCT01357681` - Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)	Phase 2
Completed	`NCT00980694` - Bioavailability of Ubiquinol in Huntington Disease	Phase 1
Completed	`NCT00146211` - TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease	Phase 3
Recruiting	`NCT01412125` - Study of Biomarkers That Predict the Evolution of Huntington's Disease	N/A
Completed	`NCT00075140` - Family Health After Predictive Huntington Disease (HD) Testing	Phase 3
Recruiting	`NCT04818060` - Preparing for Prevention of Huntington's Disease (PREVENT-HD)
Active, not recruiting	`NCT04698551` - NIPD on cffDNA for Triplet Repeat Diseases
Not yet recruiting	`NCT04301726` - Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD	Phase 1
Completed	`NCT03421327` - Genetic Risk: Whether, When, and How to Tell Adolescents
Recruiting	`NCT03296176` - Metabolomic Study in Huntington's Disease (METABO-HD)	N/A